83 related articles for article (PubMed ID: 28855206)
1. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
2. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract][Full Text] [Related]
3. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
4. Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics.
Kuric M; Beck S; Schneider D; Rindt W; Evers M; Meißner-Weigl J; Zeck S; Krug M; Herrmann M; Hartmann TN; Leich E; Rudert M; Docheva D; Seckinger A; Hose D; Jundt F; Ebert R
Cancer Res Commun; 2024 Apr; 4(4):1150-1164. PubMed ID: 38598843
[TBL] [Abstract][Full Text] [Related]
5. MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.
Katsarou A; Trasanidis N; Ponnusamy K; Kostopoulos IV; Alvarez-Benayas J; Papaleonidopoulou F; Keren K; Sabbattini PMR; Feldhahn N; Papaioannou M; Hatjiharissi E; Sudbery IM; Chaidos A; Caputo VS; Karadimitris A
Blood Adv; 2023 Nov; 7(21):6395-6410. PubMed ID: 37224458
[TBL] [Abstract][Full Text] [Related]
6. Role of Immune Cells and Immunotherapy in Multiple Myeloma.
Radhakrishnan V; Golla U; Kudva AK
Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672732
[TBL] [Abstract][Full Text] [Related]
7. Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.
Setayesh SM; Ndacayisaba LJ; Rappard KE; Hennes V; Rueda LYM; Tang G; Lin P; Orlowski RZ; Symer DE; Manasanch EE; Shishido SN; Kuhn P
NPJ Precis Oncol; 2023 Sep; 7(1):95. PubMed ID: 37723227
[TBL] [Abstract][Full Text] [Related]
8. Targeting mtDAMPed macrophages for MM therapy.
Podar K
Blood; 2023 Jun; 141(25):3012-3014. PubMed ID: 37347499
[No Abstract] [Full Text] [Related]
9. Predicting plasma cell retention and loss over a lifetime.
Robinson MJ; Tarlinton DM
Immunity; 2024 Mar; 57(3):408-410. PubMed ID: 38479357
[TBL] [Abstract][Full Text] [Related]
10. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 Ligands: The Next Big Hit?
Walenkamp AME; Lapa C; Herrmann K; Wester HJ
J Nucl Med; 2017 Sep; 58(Suppl 2):77S-82S. PubMed ID: 28864616
[TBL] [Abstract][Full Text] [Related]
12. 16-Hydroxycleroda-3, 13-dien-15, 16-olide inhibits the proliferation and induces mitochondrial-dependent apoptosis through Akt, mTOR, and MEK-ERK pathways in human renal carcinoma cells.
Liu C; Lee WC; Huang BM; Chia YC; Chen YC; Chen YC
Phytomedicine; 2017 Dec; 36():95-107. PubMed ID: 29157834
[TBL] [Abstract][Full Text] [Related]
13. The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond.
Ullah TR
J Bone Oncol; 2019 Aug; 17():100253. PubMed ID: 31372333
[TBL] [Abstract][Full Text] [Related]
14. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells
Zeissig MN; Hewett DR; Panagopoulos V; Mrozik KM; To LB; Croucher PI; Zannettino ACW; Vandyke K
Haematologica; 2021 Dec; 106(12):3176-3187. PubMed ID: 33147936
[TBL] [Abstract][Full Text] [Related]
15. Role of TAM Receptors in Antimalarial Humoral Immune Response.
John L; Vijay R
Pathogens; 2024 Apr; 13(4):. PubMed ID: 38668253
[TBL] [Abstract][Full Text] [Related]
16. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
Du J; Lin Z; Fu XH; Gu XR; Lu G; Hou J
Cell Commun Signal; 2024 Mar; 22(1):177. PubMed ID: 38475811
[TBL] [Abstract][Full Text] [Related]
17. Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.
Verbruggen SW; Freeman CL; Freeman FE
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473251
[TBL] [Abstract][Full Text] [Related]
18. Molecular and immunological mechanisms of clonal evolution in multiple myeloma.
Forster S; Radpour R; Ochsenbein AF
Front Immunol; 2023; 14():1243997. PubMed ID: 37744361
[TBL] [Abstract][Full Text] [Related]
19. Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.
Forster S; Radpour R
Front Oncol; 2022; 12():941437. PubMed ID: 35847862
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J; Besse A; Driessen C; Besse L
Front Oncol; 2022; 12():899272. PubMed ID: 35692781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
